Effect of pumpkin seed on blood sugar, fat and hereditary status of Metabolic Syndrome

Not Applicable

• Conditions: Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

• Registration Number: CTRI/2024/06/069562
• Lead Sponsor: Indian Council of Medical Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Metabolic syndrome patients aged between 18-60 years

2. Metabolic Syndrome with three or more of the following five criteria is met:

hyperglycemia, raised blood pressure, elevated triglyceride levels, low high-density

lipoprotein cholesterol levels, and central obesity [NCEP (ATP III)].

3. Patient of either sex i.e., both male and female.

4. Patient willing to consent in writing

Exclusion Criteria

1. Patient not willing to participate in the study

2. Aged less than 18 and more than 60years

3. Pregnant, nursing, or planning for pregnancy

4. Active medical condition- a known allergy or intolerance

5. Patient having any medical or surgical illness requiring priority management

6. Patient with other endocrinal diseases

7. Patient with Frank hepatorenal complication

8. Patient with chronic illness, congenital disorder, neurological and psychiatric disorder.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1.Manage reduction of Fasting blood glucose and Post prandial glucose <br/ ><br>2. Decrease HbA1c <br/ ><br>Timepoint: Glycaemic profile will be measured: <br/ ><br>First is at Baseline (at the time of patient <br/ ><br>enrollment) <br/ ><br>Second is Follow-up (after 12 weeks {3 <br/ ><br>months} of patient enrollment) <br/ ><br> <br/ ><br>

Secondary Outcome Measures

Name	Time	Method
3. Decrease Triglycerides, low-density <br/ ><br>lipoproteins Cholesterol, Total <br/ ><br>Cholesterol, Increase HDL <br/ ><br>4. Decrease IL-6 (Interleukin-6), TNFa <br/ ><br>5. Expression enhancement of Adiponectin levels & its gene expression due to alternative <br/ ><br>therapies (pumpkin seed powder)Timepoint: Anthropometric Measurements, Clinical <br/ ><br>parameters, Biochemical Parameters, genetic marker will be <br/ ><br>measured: <br/ ><br>First is at Baseline (at the time of patient <br/ ><br>enrollment) <br/ ><br>Second is Follow-up (after 12 weeks {3 <br/ ><br>months} of patient enrollment) <br/ ><br>